Key result
Six months of octreotide therapy in normotensive patients with active acromegaly significantly reduced left ventricular mass index from 138 to 116 g/m2 (P<0.001) and improved diastolic function.
Why the study?
Does octreotide improve cardiac mass and function in normotensive patients with active acromegaly?
Does octreotide improve cardiac mass and function in normotensive patients with active acromegaly?
Absolute Event Rate: 116% vs 138%
p-value: p=<0.001
Chronic treatment with octreotide for 6 months significantly improves cardiac structural and functional abnormalities in normotensive patients with active acromegaly.
No takes yet. Share an insight, caveat, or question.
Octreotide was associated with reduced LV mass and improved diastolic function; hypothesis-generating and requires RCTs before changing practice.
Merola et al. (1993) studied active acromegaly (n=11). octreotide vs. baseline (pre-treatment) was evaluated on left ventricular mass index (g/m2) (p=<0.001). Six months of octreotide therapy in normotensive patients with active acromegaly significantly reduced left ventricular mass index from 138 to 116 g/m2 (P<0.001) and improved diastolic function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: